PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$29.77
+7.32%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$28.23
From 52W high−23.39%
Volume914827.00
Market cap$2.09B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$28.23
From 52W high
−23.39%
Volume
914827.00
Market cap
$2.09B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.0x
P/E (TTM)
—
RSI (14)
33.1
MomentumView details →
1D Return
+7.32%
YTD Return
+4.65%
SummaryUpdated Jun 1, 2026
Pharvaris N.V. (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Leiden, the Netherlands. The company went public in February 2021 and operates across the Netherlands, Switzerland, and the United States. Pharvaris focuses exclusively on developing innovative therapies for hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling episodes. The company is currently advancing three drug candidates through various phases of clinical trials, with its lead compound having reached Phase II development.
Similar companies
Latest newsMore news →
Pharvaris N.V. announced positive topline results from the pivotal Phase 3 CHAPTER-3 study of deucrictibant XR for the prevention of hereditary angioedema attacks, meeting the primary endpoint with an 83% reduction in mean monthly attack rate versus placebo.41d agoPharvaris announced its financial results for the second quarter ending June 30, 2026, and provided a business update.69d agoThe U.S. FDA accepted Pharvaris's New Drug Application for deucrictibant IR for on-demand treatment of hereditary angioedema attacks.106d ago